Symbols

EXAI(Delisted)

Exscientia·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 2

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EXAI

Exscientia Limited

A artificial intelligence-driven pharmtech platform for drug design, discovery, and development

Industry

Established Date

06/29/2021

Listing Date

10/01/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

483

Fiscal Year Ends

12-31

Website

www.exscientia.ai

Security Type

Depository Receipts (Ordinary Shares)

Office address

The Schrodinger Building, Oxford Science Park, Oxford OX4 4GE, United Kingdom

Business

Introduction

Exscientia Limited was incorporated on 29 June 2021 under the laws of England and Wales. The company is an artificial intelligence-driven pharmaceutical technology company dedicated to discovering, designing and developing the best medicines in the fastest and most effective way. The company's goal is to change the essential pharmacoeconomic model of the pharmaceutical industry by improving the probability, time and cost of success, which they call the "change curve. ". The company has built complete artificial intelligence end-to-end solutions, as well as experimental technologies for target identification, drug candidate design, translational models, and patient selection. The company's platform enables them to design drug candidate molecules that have entered clinical trials and prospectively provide patients with potentially more applicable drug therapies through AI-guided evaluation.

Company Financials

EPS

EXAI has released its 2024 Q2 earnings. EPS was reported at -0.36, versus the expected -0.11, missing expectations. The chart below visualizes how EXAI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

EXAI has released its 2024 Q3 earnings report, with revenue of 6.61M, reflecting a YoY change of -39.11%, and net profit of -69.85M, showing a YoY change of -83.22%. The Sankey diagram below clearly presents EXAI's revenue sources and cost distribution.